Citalopram Versus Citalopram Plus Pindolol in Major Depressive Disorder
Information source: Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau
ClinicalTrials.gov processed this data on August 23, 2015
Link to the current ClinicalTrials.gov record.
Condition(s) targeted: Major Depressive Disorder; Antidepressant Treatment Response
Intervention: Pindolol (Drug)
Phase: Phase 2
Status: Completed
Sponsored by: Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau Official(s) and/or principal investigator(s):
Enric Ãlvarez, MD, PhD, Principal Investigator, Affiliation: Department of Psychiatry. Hospital de la Santa Creu i Sant Pau
VÃctor Pérez, MD, PhD, Study Director, Affiliation: Department of Psychiatry. Hospital de la Santa Creu i Sant Pau
Francesc Artigas, PhD, Study Chair, Affiliation: Neurochemistry department. Consejo Superior de Investigaciones CientÃficas
Summary
The purpose of this study is to examine whether the speed of the clinical antidepressant
action of citalopram can be accelerated by administering double doses of pindolol (15
mg/day, tid) which presumably should lead to increased 5-HT1A autoreceptor occupancy.
Clinical Details
Official title: Citalopram Versus Citalopram Plus Pindolol in Latency of Antidepressant Response Shortening in Major Depressive Disorder
Study design: Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment
Primary outcome: Scores on Hamilton Depression Rating Scale
Detailed description:
Design, Settings, and Participants. A randomised, double-blind, placebo-controlled trial
with MDD patients allocated to two treatment arms: citalopram + pindolol versus citalopram +
placebo. Participants: outpatients with a depressive episode (DSM-IV criteria) were selected
from a general hospital.
Eligibility
Minimum age: 18 Years.
Maximum age: 65 Years.
Gender(s): Both.
Criteria:
Inclusion Criteria:
- Patients with a depressive episode
- HDRS score > 18
- Written informed consent
Exclusion Criteria:
- suicidal risk > 3
- severe organic illness
- other psychotropic drugs
Locations and Contacts
Outpatients Service of Psychiatry Department. Hospital de la Santa Creu i Sant Pau, Barcelona, Catalonia 08025, Spain
Additional Information
Starting date: December 2002
Last updated: July 1, 2009
|
